Table 1 Representativeness of study participants
| Â | Clinical characteristics | Number |
|---|---|---|
Age | Median [min-max] | 68 [43.00,92.00] |
≤ 82 | 79 (86.81%) | |
> 82 | 12 (13.19%) | |
Gender | Female | 18 (19.78%) |
male | 73 (80.22%) | |
Urinary leucocyte counts (/uL) | Median [min-max] | 10.56 [0–3979.9] |
≤ 3.96 | 21 (23.08%) | |
> 3.96 | 70 (66.92%) | |
Urinary bacterium (/uL) | Median [min-max] | 77.88 [0–1650] |
≤ 202 | 72 (79.12%) | |
> 202 | 19 (20.88%) | |
Urinary mucus filament (/uL) | Median [min-max] | 77.88 [0–5016] |
≤ 178 | 58 (63.74%) | |
> 178 | 33 (36.26%) | |
Urinary nitrite | Negative | 78 (85.71%) |
Positive | 13 (14.29%) | |
Urinary protein | Negative | 37 (34.07%) |
+ | 39 (42.86%) | |
++ | 15 (16.48%) | |
T-stage | Ta | 28 (30.77%) |
T1 | 63 (69.23%) | |
Tumor size (cm) | ≤ 3 | 61 (67.03%) |
> 3 | 30 (32.97%) | |
Tumor grade | Low | 23 (25.27%) |
High | 68 (74.73%) | |
Tumor numbers | Single | 51 (56.04%) |
Multiple | 40 (43.96%) | |
Non-pedicled tumor | No | 57 (62.64%) |
Yes | 34 (37.36%) | |
Hemoglobin (g/L) | Median [min-max] | 141 [102–181] |
≤ 134 | 27 (29.67%) | |
> 134 | 64 (70.33%) | |
Albumin (g/L) | Median [min-max] | 42.5 [33.5–51.7] |
≤ 37.5 | 10 (10.99%) | |
> 37.5 | 81 (89.01%) | |
Lymphocyte (109/L) | Median [min-max] | 1.93 [0.69–3.87] |
≤ 1.66 | 27 (29.67%) | |
> 1.66 | 64 (70.33%) | |
Platelet (109/L) | Median [min-max] | 210 [94–417] |
≤ 200 | 32 (35.16%) | |
> 200 | 59 (64.84%) | |
HALP | Median [min-max] | 56.77 [19.42–145.63] |
≤ 35.26 | 14 (15.38%) | |
> 35.26 | 77 (84.62%) | |
Time to recurrence (months) | Median [min-max] | 12 [3.00–66.00] |